智飞生物四价流感病毒裂解疫苗、流感病毒裂解疫苗3岁以下人群扩龄申请未获批准

Core Viewpoint - The company Zhifei Biological announced the withdrawal of its registration applications for two pediatric influenza vaccines, following approval from the National Medical Products Administration [1] Group 1: Company Actions - Zhifei Biological's wholly-owned subsidiary, Zhifei Longkema, received a termination notice for the registration applications of the pediatric quadrivalent influenza virus split vaccine and the influenza virus split vaccine for the population aged 6 months to 35 months [1] - The company had previously submitted these registration applications to the National Medical Products Administration between September and October 2024, and both applications were accepted [1]